Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure
Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated